Loading…
← CockpitCompetitor Analysis › CONCORDBIO.NS Concord BiotechOpen in the cockpit ↗

Concord BiotechCONCORDBIO.NSCompetitor analysis, valuation and peers

India · INR·Commercial Services›Miscellaneous Commercial Services

Fermentation-based pharmaceutical ingredient (API) manufacturer specializing in immunosuppressants and oncology drugs.

≈ A niche fermentation-API maker, akin to a smaller Teva API armMomentum laggard 12
Mkt cap
$1.26B
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$2.50M
20-day average traded
Fwd P/E
33.9×
forward earnings
ROIC−WACC
-4.0 pp
WACC 19.2%
Hurdle
+33 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · INR₹561.00
1D+1.1%
1W-6.1%
1M-12.7%
3M-28.3%
6M-1.9%
YTD-16.6%
1Y-23.3%
ATR %5.3%
Beta0.87
52w lowhigh30.5% off high

What Concord Biotech does

Fermentation-based pharmaceutical ingredient (API) manufacturer specializing in immunosuppressants and oncology drugs.

Grows microbes in large fermentation tanks to produce active ingredients, such as the transplant-rejection drug tacrolimus, and sells them in bulk to generic drug makers, competing on yield, quality and regulatory approvals in each market. It listed on the stock market in 2023.

In one line: A niche fermentation-API maker, akin to a smaller Teva API arm.

Products and services

  • Immunosuppressant APIs
  • Oncology APIs
  • Other fermentation-based APIs

Customers

  • Global generic drug manufacturers
  • Pharmaceutical formulation companies

Where it sits in the supply chain

  • Pharmaceuticals
  • Active pharmaceutical ingredient (API)…
  • Fermentation-based APIs…

What could go right

  • Growing global generics demand for complex APIs
  • China+1 API sourcing diversification

What could go wrong

  • Regulatory (FDA) inspection/compliance risk
  • Customer concentration in generics manufacturers

Moat: narrow (process know-how, regulatory licence). Complex fermentation-based API manufacturing expertise and regulatory approvals create high entry barriers.

Headquarters: Ahmedabad, India · Founded: 1984 · Employees: 1,624

Named competitors

Concord Biotech at a glance

Size Concord Biotech (CONCORDBIO.NS) is an India Industrials company (Miscellaneous Commercial Services) with a market value of $1.26B, the 539th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹561.00 on 18 Nov 2026.

Performance Over six months the shares fell 1.9%, against -19.7% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 4.0% over the last twelve months (peer median +10.0%); the operating margin is 28.1% (peer median 9.6%).

Valuation It trades at 33.9× forward earnings against a peer median of 27.1× (8th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points below its cost of capital (19.2% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026CONCORDBIO.NS 101Peer median 81
Six months, rebased to 100: Concord Biotech against the median of its 20 peers (local-currency closes).

Concord Biotech financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹11.7B₹10.5B₹11.8B₹9.98B₹8.31B
Revenue growth—-11%+18%+20%—
Gross profit₹4.96B₹4.17B₹5.54B₹4.72B₹3.71B
EBITDA₹4.04B₹3.71B₹4.96B₹4.19B₹3.33B
Net income₹2.82B₹2.61B₹3.72B₹3.08B₹2.40B
Free cash flown/a₹1.74B₹1.36B₹1.82B₹1.06B
Capital expendituren/a₹952M₹1.11B₹857M₹1.45B
Total debt₹17.5M₹23.2M₹29.7M₹97.4M₹315M

Quarterly statements and history in the cockpit →

Concord Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%688800688351974668811260311200233860065468812815152384CRAI300725RHLDDBG688252CLVTCMPDI688202301413002607CONCORDBIO.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Concord Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×68880068835197466881126031120023382384CRAI300725DBGCLVT688202301413002607CONCORDBIO.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Concord Biotech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%-25%0%25%50%6888006883519746688112603112600654688128CRAI300725DBG688252CLVTCMPDI002607CONCORDBIO.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Concord Biotech is the large dot.

Concord Biotech competitors and peer comparison

Head to head with its named competitors (CONCORDBIO.NS vs DIVISLAB.NS vs BIOCON.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Concord Biotech CONCORDBIO.NS$1.26B-2%+4%28%33.9×44.4%
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Biocon BIOCON.NS$6.31B-15%+6%8%61.3×n/a

How Concord Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Concord Biotech against its 20 peers (data as of 18 Nov 2026)
MeasureCONCORDBIO.NSPeer medianRank in peer set
1-month return-12.7%-2.3%6th lowest of 21
6-month return-1.9%-19.7%7th highest of 21
Distance from 52-week high-30.5%-37.7%7th highest of 21
Revenue growth (TTM)+4.0%+10.0%5th lowest of 21
Operating margin28.1%9.6%2nd highest of 21
Forward P/E33.9×27.1×8th most expensive of 17
Growth the price implies (Req g, 7 yrs)44.4%12.6%2nd most demanding of 17
Growth delivered (Del g)+11.6%+14.1%6th lowest of 16
Hurdle (Req g minus delivered)+32.8 pp-1.5 pp3rd most demanding of 16
ROIC minus cost of capital-4.0 pp-0.9 pp7th lowest of 21
EV / EBITDA27.9×8.4×most expensive of 9
Net debt / EBITDA-1.1×1.8×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Concord Biotech CONCORDBIO.NSIndia$1.26B-2%+4%28%33.9×44.4%+11.6%
Suzhou Recodeal Interconnect System 688800.SSChina$1.26B-68%+5%9%31.0×22.7%+38.9%
Shanghai MicroPort EP Medtech 688351.SSChina$1.31B-30%+20%3%137.1×42.5%+26.7%
TKC 9746.TJapan$1.31B+22%+5%20%19.1×-10.1%+5.7%
Siglent Technologies 688112.SSChina$1.19B-26%+30%24%39.2×27.7%+22.0%
Shanxi Huaxiang 603112.SSChina$1.19B-33%+9%11%11.6×0.9%+16.2%
Changchun Up Optotech 002338.SZChina$1.34B-41%+22%2%43.1×n/an/a
China Security 600654.SSChina$1.34B-31%-30%-1%n/a56.0%+0.4%
China National Electric Apparatus Research Institute 688128.SSChina$1.35B-17%+8%11%14.7×3.2%+13.5%
Nittetsu Mining 1515.TJapan$1.17B-3%+18%8%n/an/an/a
SBS 2384.TJapan$1.35B+26%+17%5%13.9×-4.7%+13.8%
CRA International CRAIUnited States$1.35B+46%+13%10%23.3×6.6%+8.1%
PharmaBlock Sciences (Nanjing) 300725.SZChina$1.36B+5%+11%11%37.5×24.2%+14.1%
Resolute Holdings Management RHLDUnited States$1.16B+34%+10%12%n/a16.6%n/a
Derichebourg DBG.PAFrance$1.37B-18%-3%5%8.8×6.7%+6.3%
Jadard Technology 688252.SSChina$1.14B-22%+6%12%22.3×12.0%+31.3%
Clarivate CLVTUnited States$1.38B-12%-9%8%3.5×13.2%+14.4%
Central Mine Planning & Design Institute CMPDI.NSIndia$1.38B-22%+10%33%n/a4.5%+18.7%
Shanghai Medicilon 688202.SSChina$1.39B+8%+42%-2%85.1×n/an/a
Shenzhen Ampron Technology 301413.SZChina$1.40B-28%+11%2%387.2×n/an/a
Offcn Education Technology 002607.SZChina$1.40B-40%-2%13%34.7×15.7%-27.6%

Questions

Who are Concord Biotech's main competitors?
Named competitors: Divi's Laboratories (DIVISLAB.NS), Biocon (BIOCON.NS). The cockpit's measured peer set (industry) also includes Suzhou Recodeal Interconnect System (688800.SS), Shanghai MicroPort EP Medtech (688351.SS), TKC (9746.T), Siglent Technologies (688112.SS), Shanxi Huaxiang (603112.SS), Changchun Up Optotech (002338.SZ).
Is Concord Biotech expensive compared with its peers?
On forward p/e it trades at 33.9× against a peer median of 27.1×, 8th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Concord Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -1.9% against -19.7% for the median peer; over one year -23.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.